Status:
UNKNOWN
Ropivacaine/Dexamethasone and 10% Lignocaine Injection in GPN Block for Intractable Cancer Pain
Lead Sponsor:
All India Institute of Medical Sciences
Conditions:
Cancer, Oropharynx
Pain, Intractable
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The study will compare the efficacy and safety of Ropivacaine/dexamethasone vs 10% lignocaine injection in distal glossopharyngeal nerve block for intractable cancer pain
Eligibility Criteria
Inclusion
- Patients with proven carcinoma of the oropharynx and supraglottic larynx with estimated survival of 3 months or more.
- Pain lasting for at least 2 weeks with an average intensity of 5 or more on an 11-point numeric rating scale (NRS) refractory to a combination strong opioids and NSAIDS
Exclusion
- Local infection or skin ulceration at the puncture site
- Local anaesthetic allergy
- Psychiatric illness that affected cooperation.
Key Trial Info
Start Date :
August 23 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 28 2020
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04085120
Start Date
August 23 2019
End Date
February 28 2020
Last Update
September 11 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
All India Institute of Medical Sciences
New Delhi, National Capital Territory of Delhi, India, 110029